Description of Emmis Acquisition's Business Segments
Emisphere Technologies Inc. is a biopharmaceutical company focused on developing proprietary delivery technologies to enhance the absorption and bioavailability of therapeutics that are otherwise poorly absorbed when taken orally. Below is an extensive description of the segments, products, and services that Emisphere Technologies has historically offered.
Segments
1. Drug Delivery Technology: The primary segment of Emisphere Technologies is its innovative drug delivery platform known as Eligen®. This technology utilizes carrier molecules to facilitate the transport of drugs across biological membranes, improving oral absorption.
2. Partnership and Collaboration: The company engages in various partnerships with established pharmaceutical companies to develop and commercialize new drug formulations utilizing its delivery technology. This segment reflects the collaborative nature of drug development in the biopharma industry.
3. Research and Development (R&D): Emisphere invests heavily in research and development to enhance its drug delivery technologies and explore new therapeutic applications. This segment focuses on both improving existing technologies and developing new products.
Products
1. Eligen® Technology: This is the cornerstone of Emispheres product offerings. The Eligen® platform allows for oral delivery of peptides, proteins, and other large molecules that typically require injection. The capability to enhance bioavailability through this technology positions it as a valuable solution for many therapeutic areas.
2. Bromocriptine Mesylate (Corgenix): Emisphere has utilized its Eligen® technology to facilitate the oral delivery of bromocriptine, a medication used to treat conditions like Parkinsons Disease and hyperprolactinemia. The formulation aims to improve patient compliance by providing an oral alternative to injections.
3. GLP-1 Receptor Agonists: Emisphere has explored the use of its technology to improve the oral bioavailability of GLP-1 receptor agonists, which are used to manage type 2 diabetes. This potential product would enable patients to manage diabetes more easily without the need for injections.
4. Calcium-sensing Receptor Antagonists: The company has also investigated developing a novel delivery system for calcium-sensing receptor antagonists to treat various metabolic diseases.
5. Other Peptide and Protein-based Therapies: Emisphere has worked on several other therapeutics across different therapeutic areas, focusing on improving the oral delivery of biologics that are traditionally administered via injections.
Services
1. Licensing Agreements: Emisphere offers licensing agreements for its proprietary Eligen® technology, allowing pharmaceutical companies to leverage its drug delivery system in their own product development. This aspect expands the reach of its technology into the broader pharmaceutical market.
2. Formulation Development: Emisphere provides formulation development services that assist partners in optimizing their therapeutic candidates for improved oral bioavailability using Eligen® technology.
3. Consultative Support: The company provides consultative services for healthcare organizations and pharmaceutical companies seeking expertise in drug formulation and delivery technologies. This can include strategic guidance on product development and regulatory pathways.
4. Partnership Development: Emisphere is involved in building strategic partnerships with biopharmaceutical companies. This includes co-development contracts, sharing expertise, and resources in drug delivery innovations.
5. Clinical Research Support: Emisphere may offer support in designing and conducting clinical trials for therapeutics developed using its delivery systems, helping to validate safety and efficacy.
Conclusion
Emisphere Technologies Inc. stands out for its commitment to advancing drug delivery technologies that enhance the option for oral administration of therapeutics traditionally limited to needle-based delivery. Through its innovative Eligen® technology, diverse product pipeline, and strategic collaborations with pharmaceutical companies, Emisphere aims to bridge the gap between the efficacy of injectable therapies and patient-friendly oral dosing. The company’s focus on research and partnerships drives the exploration of new therapeutic possibilities in the rapidly evolving biopharmaceutical landscape.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
